Novo Nordisk has defended disappointing trial results for its much-hyped next generation obesity drug candidate CagriSema, ...
CNBC on MSN9d
Novo Nordisk's next-gen obesity drug CagriSema had investors excited. Now they're not so sureNovo Nordisk's hopes of heralding a new era of obesity treatment with its CagriSema drug have been called into question after ...
3don MSN
The results pave the way for Rybelsus to become a new treatment option for people living with diabetes and established heart ...
Novo Nordisk is taking aim at Eli Lilly with a new obesity drug deal. Meanwhile, a survey shows doctors’ perception of the ...
Bank of America analysts on Friday said Novo Nordisk may miss first-quarter expectations, as sales of its blockbuster Wegovy ...
Novo Nordisk to Pay $2 Billion for New Weight Loss Drug TUESDAY, March 25, 2025 (HealthDay News) -- Novo Nordisk, a Danish pharmaceutical company, has signed a major deal worth up to $2 billion ...
Novo Nordisk said Thursday that the rampant growth of the U.S.’ compounded drug industry was hurting Wegovy sales, and warned ...
It stressed that while the funding came from the Novo Nordisk Foundation, the project itself would be carried out by ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback